Treatment of idiopathic anaphylaxis with omalizumab

Idiopathic anaphylaxis (IA) is a rare condition that can be lethal.1 Prophylactic regimens for frequent attacks are not yet standardized. These treatments may include long-term systemic corticosteroids, high-dose antihistamines, and mast cell stabilizers. Despite these regimens, patients may become corticosteroid dependent (20%) and develop potential adverse effects.2 Omalizumab is a monoclonal anti-IgE antibody that is indicated in uncontrolled, moderate to severe, persistent asthma3 and chronic idiopathic urticaria.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Letters Source Type: research